Epigenomics to Launch Epi proColon in Israel with Marketing Partner Pronto Diagnostics | GenomeWeb

Berlin-based Epigenomics and Pronto Diagnostics this week signed an exclusive distributor agreement for the commercialization of Epigenomics' Epi proColon test in Israel.

Epi proColon is a test for the early detection of colorectal cancer. The blood-based test interrogates Epigenomics' proprietary Septin 9 biomarker.

Pronto Diagnostics plans to start marketing the test in Israel in November.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.